Parallel Advisors LLC increased its position in shares of Sanofi (NYSE:SNY) by 42.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,934 shares of the company’s stock after buying an additional 875 shares during the period. Parallel Advisors LLC’s holdings in Sanofi were worth $139,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Fisher Asset Management LLC increased its stake in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares during the last quarter. Global Financial Private Capital LLC bought a new stake in Sanofi during the first quarter worth about $35,034,000. Karp Capital Management Corp bought a new stake in Sanofi during the first quarter worth about $26,174,000. Bank of America Corp DE increased its stake in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Sanofi by 1,298.6% in the first quarter. Russell Investments Group Ltd. now owns 565,750 shares of the company’s stock worth $25,596,000 after buying an additional 525,300 shares during the last quarter. Hedge funds and other institutional investors own 9.33% of the company’s stock.

Sanofi (NYSE SNY) opened at 48.96 on Wednesday. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The stock’s 50 day moving average is $47.93 and its 200-day moving average is $46.69. The firm has a market capitalization of $122.96 billion, a PE ratio of 11.61 and a beta of 0.88.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. Equities analysts expect that Sanofi will post $3.26 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/sanofi-sny-position-increased-by-parallel-advisors-llc.html.

SNY has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Friday, June 2nd. BidaskClub raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Argus lifted their price target on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, June 9th. Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the stock. Sanofi presently has an average rating of “Hold” and a consensus price target of $54.00.

In other news, major shareholder Sanofi bought 60,595 shares of the stock in a transaction on Wednesday, August 23rd. The stock was acquired at an average price of $478.98 per share, with a total value of $29,023,793.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.00% of the stock is owned by corporate insiders.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.